NeuroOne Announces 1-for-6 Reverse Stock Split to Regain Nasdaq Compliance

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a pioneering medical technology company dedicated to transforming surgical diagnosis and treatment for neurological disorders, has announced a significant corporate action: a 1-for-6 reverse stock split of its common stock. This strategic move, approved by stockholders at the company's 2026 annual meeting and subsequently authorized by the Board of Directors, will take effect after market close on April 15, 2026, with trading on a split-adjusted basis commencing at market open on April 16, 2026. The primary objective behind this reverse stock split is to help NeuroOne regain compliance with the Nasdaq Capital Market's minimum bid price requirement, ensuring continued listing under the symbol "NMTC" with an updated CUSIP number. This development follows the company's disclosure on www.newmediawire.com, highlighting its commitment to maintaining market presence while advancing its innovative medical technologies.

The reverse stock split will uniformly affect all stockholders, converting every six shares of outstanding common stock into one share without altering the $0.001 par value or authorized share count. Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive cash payments, ensuring fair treatment. Additionally, proportionate adjustments will be made to the company's outstanding stock options, exercise prices, and equity incentive plans, maintaining alignment with the new share structure. NeuroOne's focus remains on its core mission: improving surgical care for neurological patients through its FDA-cleared product families, including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, and OneRF® Ablation Systems, which aim to reduce hospitalizations, lower costs, and enhance patient outcomes. For more details, stakeholders can visit nmtc1.com to explore the company's advancements in drug delivery and spinal cord stimulation research.

This announcement underscores NeuroOne's proactive approach to corporate governance and financial stability, as it navigates regulatory requirements while continuing to innovate in the medical technology sector. The reverse stock split, set within a Board-approved range of 1-for-2 to 1-for-15, reflects careful planning to optimize market positioning without diluting shareholder equity, except for minor adjustments due to fractional shares. By addressing Nasdaq compliance, NeuroOne aims to bolster investor confidence and support its long-term growth strategy, which includes expanding its portfolio of minimally invasive, high-precision solutions for neurological disorders. As the company moves forward, stakeholders should monitor its progress in regaining listing compliance and advancing its therapeutic technologies, which hold promise for transforming patient care in neurology.